Corrigendum: Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID

Goh, Denise; Lim, Jeffrey Chun Tatt; Fernaíndez, Sonia Bilbao; Joseph, Craig Ryan; Edwards, Sara Gil; Neo, Zhen Wei; Lee, Justina Nadia; Caballero, Sílvia Guerrero; Lau, Mai Chan; Yeong, Joe Poh Sheng

doi:10.3389/fimmu.2022.1036894

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenetic mechanisms leading to severe COVID-19 disease involve endothelial dysfunction, hyperactivation of the immune system and immune-thrombosis; these all require early intervention to prevent the high risk of venous thromboembolism that may lead to death [ 4 , 5 , 6 , 7 , 8 , 9 ] or to the long-term residual effects of COVID-19-associated coagulation found in long COVID patients [ 46 ]. Recent studies have reported the possibility of viral persistence as a driver of long COVID [ 43 , 44 ]; viral proteins and/or RNA have indeed been found in lymph nodes, hepatic tissue, lung tissue, plasma, stool, and urine of some patients [ 47 , 48 ]. Studies performed by analyzing the coagulation profile of long COVID patients have described a pro-coagulant state with an ongoing process of thrombi formation and/or persistent microthrombosis in 30% of patients after 12–18 months of follow-up [ 46 ], underlying the need to further investigate the etiology of COVID-19-associated coagulopathy for the early management of coagulation disorders [ 49 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4

Spinello,

Saulle,

Quaranta

et al. 2024

Viruses

View full text Add to dashboard Cite

Coagulation disorders are described in COVID-19 and long COVID patients. In particular, SARS-CoV-2 infection in megakaryocytes, which are precursors of platelets involved in thrombotic events in COVID-19, long COVID and, in rare cases, in vaccinated individuals, requires further investigation, particularly with the emergence of new SARS-CoV-2 variants. CD147, involved in the regulation of inflammation and required to fight virus infection, can facilitate SARS-CoV-2 entry into megakaryocytes. MCT4, a co-binding protein of CD147 and a key player in the glycolytic metabolism, could also play a role in SARS-CoV-2 infection. Here, we investigated the susceptibility of megakaryocytes to SARS-CoV-2 infection via CD147 and MCT4. We performed infection of Dami cells and human CD34+ hematopoietic progenitor cells induced to megakaryocytic differentiation with SARS-CoV-2 pseudovirus in the presence of AC-73 and syrosingopine, respective inhibitors of CD147 and MCT4 and inducers of autophagy, a process essential in megakaryocyte differentiation. Both AC-73 and syrosingopine enhance autophagy during differentiation but only AC-73 enhances megakaryocytic maturation. Importantly, we found that AC-73 or syrosingopine significantly inhibits SARS-CoV-2 infection of megakaryocytes. Altogether, our data indicate AC-73 and syrosingopine as inhibitors of SARS-CoV-2 infection via CD147 and MCT4 that can be used to prevent SARS-CoV-2 binding and entry into megakaryocytes, which are precursors of platelets involved in COVID-19-associated coagulopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4

Spinello,

Saulle,

Quaranta

et al. 2024

Viruses

View full text Add to dashboard Cite

show abstract

“…One of the hypotheses regarding pathogenesis of long COVID is that it might be linked to prolonged inflammation probably due to viral antigens persistence [43]. Monoclonal antibodies prevent the viral attachment to the cells blocking the binding of the virus to the human angiotensin-converter enzyme 2 receptor (ACE2) that is highly expressed on the surface of oligodendrocytes, which could explain the virus proliferation in nerve tissue cells and subsequent neurological damage and sequelae [44,45].…”

Section: Discussionmentioning

confidence: 99%

The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study

et al. 2023

View full text Add to dashboard Cite

Purpose Oral antivirals (nirmatrelvir/ritonavir and molnupiravir), intravenous short treatment of remdesivir and anti-SARS-CoV-2 monoclonal antibodies (mAbs) have been used for early COVID-19 treatments in high risk of disease progression patients. The term long COVID has been used to refer to a range of new, returning, or ongoing symptoms after SARS-CoV-2 infection. Little is known about the impact of such therapies on long COVID. Methods This is a retrospective observational study, including all outpatients evaluated from April 2021 to March 2022 in Brescia, Lombardy, northern Italy. Patients were stratified in three groups: (a) treated with mAbs, (b) treated with antivirals drugs and (c) controls (patients eligible for a or b who refused treatment). Data were collected at baseline and at month 1 and 3 (data on self-reported symptoms were collected using a telephone-administered questionnaire). We assessed early COVID-19 therapies effectiveness in preventing hospitalization, death at 1 or 3 months and persisting symptoms at 3 months after the onset of SARS-CoV-2 infection. Results A total of 649 patients were included in the study, of which 242 (37.3%) were treated with mAbs, 197 (30.3%) with antiviral drugs and 210 (32.4%) were not treated. Patients most frequently reported cerebro-cardiovascular diseases (36.7%) followed by obesity (22%). Overall, 29 patients (4.5%) died or were hospitalized at 1 or 3-month follow-up. Death or hospitalization was positively associated with older ages, with a significant linear trend (OR 3.05; 95% CI 1.16–8.06, for patients aged 80 or more years compared to those aged less than 65). Data on long COVID at 3 months were available for 323 (49.8%) patients. A positive association emerged for females compared to men, with an OR of 2.14 (95% CI 1.30–3.53) for any symptoms. Conversely, inverse associations were found for treatment groups as compared to the control one, with significant estimates among patients treated with antiviral drugs for any symptoms (OR 0.43, 95% CI 0.21–0.87) and patients treated with mAbs for any neuro-behavioral symptoms (OR 0.48, 95% CI 0.25–0.92). Conclusions We report beneficial effect of early use of anti-SARS-CoV-2 antivirals and mAbs on long COVID.

show abstract

Long-term gastrointestinal outcomes of COVID-19

Al‐Aly

2023

Nat Commun

View full text Add to dashboard Cite

A comprehensive evaluation of the risks and 1-year burdens of gastrointestinal disorders in the post-acute phase of COVID-19 is needed but is not yet available. Here we use the US Department of Veterans Affairs national health care databases to build a cohort of 154,068 people with COVID-19, 5,638,795 contemporary controls, and 5,859,621 historical controls to estimate the risks and 1-year burdens of a set of pre-specified incident gastrointestinal outcomes. We show that beyond the first 30 days of infection, people with COVID-19 exhibited increased risks and 1-year burdens of incident gastrointestinal disorders spanning several disease categories including motility disorders, acid related disorders (dyspepsia, gastroesophageal reflux disease, peptic ulcer disease), functional intestinal disorders, acute pancreatitis, hepatic and biliary disease. The risks were evident in people who were not hospitalized during the acute phase of COVID-19 and increased in a graded fashion across the severity spectrum of the acute phase of COVID-19 (non-hospitalized, hospitalized, and admitted to intensive care). The risks were consistent in comparisons including the COVID-19 vs the contemporary control group and COVID-19 vs the historical control group as the referent category. Altogether, our results show that people with SARS-CoV-2 infection are at increased risk of gastrointestinal disorders in the post-acute phase of COVID-19. Post-covid care should involve attention to gastrointestinal health and disease.

show abstract

Corrigendum: Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID

Abstract: A Corrigendum onCase report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID

Cited by 10 publications

References 0 publications

AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4

AC-73 and Syrosingopine Inhibit SARS-CoV-2 Entry into Megakaryocytes by Targeting CD147 and MCT4

The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study

Long-term gastrointestinal outcomes of COVID-19

Contact Info

Product

Resources

About